Trade now with Barclays Stockbrokers
05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
Carolyn Cross |
156,314,029 |
£13,677,478 |
Nicolas Loebel |
3,538,991 |
£309,662 |
Junaid Bajwa |
1,193,697 |
£104,448 |
Jean Duvall |
1,163,529 |
£101,809 |
Jean Charest |
353,356 |
£30,919 |
Simon Sinclair |
256,327 |
£22,429 |
Carolyn Cross |
118,091,377 |
£10,332,996 |
M&G Plc |
40,588,235 |
£3,551,471 |
Robert Cross |
25,858,400 |
£2,262,610 |
Albemarle Life Sciences Fund |
15,105,882 |
£1,321,765 |
CRUX Asset Management |
9,298,090 |
£813,583 |
Chelverton Asset Management |
7,957,311 |
£696,265 |
11:25 |
100 @ 9.00p |
11:25 |
700 @ 9.00p |
09:57 |
100,000 @ 9.10p |
10:15 |
53 @ 8.50p |
10:03 |
50,000 @ 8.80p |
Chair |
Jean Charest |
CEO |
Carolyn Cross |
Top of Page
You are here:
research